RxDoctor Payments DataLook up a doctor →

Edgardo Laurel, MD

Nephrology · Phoenix, AZNPI 1992708788

Payments from drug & device makers

$14,764in general payments, 2019–2025

Across 533 payments — averaging $27.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • Otsuka America Pharmaceutical, Inc.$877
  • Boehringer Ingelheim$623
  • Bayer$569
  • ANI Pharmaceuticals, Inc.$564
  • Novo Nordisk$563
  • plus $6K from 33 others

What the payments were for

  • Consulting fees$4,19828%
  • Travel & lodging$1571%
  • Food & beverage$10,23069%
  • Education$1791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,764 in reported general payments places this provider in the 85th percentile of 259 nephrology providers in Arizona.

See all nephrology providers in Arizona

Medicare billing

Part B allowed, 2024
$67,595
Medicare patients
305
Services billed
1,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol206$141,817
JardianceEmpagliflozin196$135,853
KerendiaFinerenone30$35,561
OzempicSemaglutide16$16,083
ProcritEpoetin Alfa12$13,356
Fluconazole279$9,918
DapagliflozinDapagliflozin Propanediol17$8,748
EntrestoSacubitril/Valsartan13$8,367
Mycophenolic AcidMycophenolate Sodium13$5,809
Cinacalcet Hcl38$5,154
ProsolParenteral Amino Acid 20% No.113$2,750
Leflunomide23$2,249
Calcitriol51$2,124
Mycophenolate Mofetil15$2,045
Tacrolimus30$1,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$6,038$141,817206 claims
Boehringer IngelheimJardiance$623$135,853196 claims
BayerKerendia$569$35,56130 claims
Novo NordiskOzempic$563$16,08316 claims
NovartisEntresto$88$8,36713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 259 nephrology providers in Arizona.

Other nephrology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →